Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2025 Jul 26;45(6):1359–1375. doi: 10.1111/opo.13550

Visual field defects in dementia: A scoping review

Jack Phu 1,2,3,4,✉, Henrietta Wang 1,2
PMCID: PMC12357235  PMID: 40716026

Abstract

Introduction

This review aimed to systematically assess the literature reporting the relationship between dementia and standard automated perimetry results, including sensitivity, global indices, patterns of visual field defect and reliability indices.

Design

A scoping review and meta‐analysis were conducted.

Setting and Participants

Published studies in any setting which reported on standard automated perimetry results (any of: global indices, pointwise sensitivities, reliability indices and/or patterns of visual field defects) in participants with (‘cases’) or without (‘controls’) dementia due to neurodegenerative disease.

Methods

Four databases were searched (to July 2024) and included published studies comparing the perimetry results of cases and controls. Standardised mean differences with 95% confidence intervals were calculated where data were available. Studies with qualitative visual field results were identified and described. The Joanna Briggs Institute checklists were used for quality assessment.

Results

Four studies were included in the meta‐analysis component of the study. Standardised mean differences between cases and controls were −1.16 (−1.47, −0.86) and −0.96 (−1.26, −0.67) for mean deviation and pattern standard deviation, respectively. The standardised mean differences for fixation loss, false positive and false negative rates were −0.30 (−0.57, −0.04), −0.33 (−0.60, −0.06) and −1.12 (−1.40, −0.83), respectively. In all instances, cases had poorer results than controls. Hemianopias were the most common visual field defect pattern, followed by quadrantonopia, with left‐sided defects more common than right. Several studies illustrated visual field sensitivity and deviation maps, from which examples of inattentive defects were identified.

Conclusions

Cross‐sectional studies, case series and case reports demonstrated worse visual function and reliability indices in patients with dementia in comparison to controls. Several knowledge gaps and opportunities for further study were identified, including potentially using patterns of poor test reliability and inattention as surrogate markers of cognitive impairment and its relationship with quantitative evaluation of cognitive function.

Keywords: Alzheimer's, perimetry, posterior cortical atrophy, reliability, standard automated perimetry, visual fields


Key points.

  • Perimetric indices of visual function are poorer in patients with dementia in comparison with healthy controls.

  • Measures of perimetric test reliability, including fixation losses, false positives and false negatives, are higher (worse) in patients with dementia in comparison with healthy controls.

  • Quantitative and qualitative indices of visual function and reliability on perimetric testing may serve as surrogate markers of cognitive impairment.

INTRODUCTION

Dementia describes a group of cognitive changes occurring as a common feature of many neurodegenerative aetiologies. 1 Typical symptoms include a decline in memory, thinking, behaviour, motor control, emotion and language functions. It is a significant cause of morbidity and mortality worldwide. 2 The most common cause of dementia is Alzheimer's disease, followed by vascular dementia, Lewy body dementia and frontotemporal dementia. 3 As there is no cure for dementia, prevention and early case detection to institute suitable interventions are important for reducing the morbidity and mortality associated with the condition. 1

Dementia is a clinical endpoint, and diagnosis of the core disease, such as Alzheimer's disease, is traditionally based upon clinical criteria, which commonly reflect a spectrum of functional change. 4 Several methods for early detection of neurodegenerative conditions leading to dementia are in clinical use, such as cerebrospinal fluid testing, magnetic resonance imaging and positron emission tomography. 5 Other novel biomarkers have also been suggested in the literature. 6 However, these have limitations, including invasiveness, inconvenience and cost, making them currently impractical for routine screening purposes.

The eye has been investigated as a proxy for visualising neurodegenerative changes occurring in the brain. 7 As an extension of the brain, retinal and optic nerve changes have been described in animal and human models of neurodegeneration, such as Alzheimer's disease. 7 Optical coherence tomography imaging has revealed non‐specific loss of retinal tissue, such as retinal nerve fibre layer thinning, in patients with neurodegeneration of the brain. 8 Surrogate markers of amyloid plaque burden in the brain include vascular changes in the eye. 9 , 10 More advanced imaging modalities have highlighted amyloid plaques in the retina in in vivo animal models and post‐mortem human eyes, 11 , 12 , 13 in line with histopathological studies of retinal tissue.

Alongside the structural changes appreciable on retinal examination, output visual functions have also been investigated in the context of neurodegenerative changes. 14 Deficits in vision, such as in the visuospatial domain, are part of diagnostic criteria for various aetiologies of dementia, representing higher level functions governed by the cortical regions of the visual pathway. 4 , 15 , 16 , 17 In addition to neuropsychiatric testing batteries, routine ophthalmological vision tests have been shown to reveal poorer functionality in people with dementia. 14

A commonly used ophthalmological test is standard automated perimetry, through which a quantitative assessment of contrast sensitivity across the visual field is performed. 18 , 19 In brief, a uniform incremental light stimulus is presented upon a uniform background, and the patient responds when they see the target. Typically, the stimulus intensity is adjusted based on the response until an estimate of threshold sensitivity is obtained, per the thresholding algorithm. The threshold therefore represents an estimation of differential light sensitivity at that location: the difference between stimulus and background where there is a just noticeable difference in intensity. In addition to reporting quantitative values, such as pointwise sensitivity and mean deviation, patterns of visual field defects are also interpreted by clinicians and correlated with examination of the structures of the visual pathway for clinical diagnosis and functional evaluation. 18 , 19 Typically, patterns of visual field defects are interpreted using greyscale (visual representation of differential light sensitivity) and deviation maps (representing differences from an underlying, age‐corrected normative database and the probability of normality based on the distribution). Common ophthalmic conditions such as glaucoma have characteristic perimetric findings that aid in the diagnostic process. 18 , 19

Use of perimetry in the context of neurodegenerative disease has been reported in the literature. 14 Mean deviation has been shown to be significantly reduced in people with dementia and Alzheimer's disease in comparison to controls, indicating generalised visual field sensitivity loss. 14 Previous studies have also highlighted variants of neurodegeneration, such as posterior cortical atrophy, presenting with typical patterns of visual field defects due to the specific locations of brain matter loss. 20 , 21

In addition to quantitative and qualitative findings of standard automated perimetry, the instrument also returns a set of ‘reliability’ metrics. 18 , 22 These include the results of catch trials, such as fixation losses, false positives and false negatives, or computerised gaze tracking. Qualitative patterns of low test reliability have been well described in the literature, such as cloverleaf defects and seeding point errors, 23 , 24 thought to reflect different aspects of patient behaviours leading to suboptimal perimetric results. Since dementia represents a constellation of cognitive decline, it follows that quantitative (i.e., catch trials) and qualitative (i.e., patterns of visual field ‘defects’) artefacts related to low test reliability may also accompany sensitivity losses identified on standard automated perimetry.

In addition to the effects of dementia on vision testing, visual impairment has also been linked to an increased risk of onset of dementia. Similar to hearing loss, correctable vision impairment may be a modifiable risk factor for dementia in later life. 25 , 26 Several mechanisms for vision impairment leading to dementia or cognitive decline have been proposed, such as social isolation and reduced activation of central sensory pathways. 27 This is an emerging field of research as causation is difficult to prove, as the relationship is bidirectional. 28

The purpose of this scoping review was to synthesise evidence pertaining to patterns of visual field defects, including low test reliability artefacts, in dementia, focussing on its neurodegenerative aetiologies. Identifying potential patterns of visual field defects in dementia (particularly in its early stages) may provide a means for case detection with a simple routine clinical test, and to also aid in distinguishing neurodegeneration from other diseases of the visual pathway such as glaucoma. Even if testing is conventionally deemed to be "unsuccessful" due to issues of reliability or variability in later disease, it may be possible to identify markers of cognitive neurodegeneration from the testing process or through patterns of unreliability. 29 , 30 , 31 By perusing the literature, this study aimed to identify gaps in the knowledge and discuss opportunities for future research, so as to better understand dementia and the visual pathway.

METHODS

The protocol for this review was registered in PROSPERO, and reporting followed the Preferred Reporting Items for Systematic Reviews and Meta‐Analysis extension for Scoping Reviews (PRISMA‐ScR) guidelines. 32 A scoping review was chosen after initially determining that there was a paucity of literature available for a full systematic review and meta‐analysis, and thus the goal was to identify knowledge gaps and issues, and to generate novel ideas for future research. 33 A recent meta‐analysis broadly examined visual functions in dementia, 14 but the goal was to delve deeper into the qualitative patterns of visual field defect and reliability, both of which are relevant for distinguishing between dementia‐related perimetric loss and other organic pathologies of the visual pathway.

Inclusion and exclusion criteria

Published studies in any setting (see further below) were included, which reported on standard automated perimetry results (any of global indices, pointwise sensitivities, reliability indices and/or patterns of visual field defects) in participants with (‘cases’) or without (‘controls’) dementia due to neurodegenerative disease. Dementia due to causes other than neurodegenerative disease, such as infective aetiologies, were not included. The diagnosis of dementia was required to have been made according to any established diagnostic criteria (such as the Diagnostic and Statistical Manual of Mental Disorders) or methods (such as clinical criteria).

All study designs were included, but case reports and case series were excluded from the quantitative analysis portion of the present study. Studies were excluded if they had selective sampling, were in the context of other diseases (such as diseases of the visual pathway) or were reported only as abstracts (including conference papers or posters). While it was initially planned to include only observation studies as they would be better suited for assessing parameters such as frequency/prevalence and associations in a more unmanipulated setting, a second review of records was performed to identify experimental studies that might also contain suitable data. It was noted that the design of some randomised clinical trials, which may be to explore specific research questions, may preclude their inclusion as their participants may not represent suitable data due to specific or stringent inclusion (such as requiring a specific type of visual field defect) and exclusion (such as being unable to undertake visual field testing) criteria. The inclusion and exclusion criteria are also summarised in Table 1. Case series and case studies were assessed separately for qualitative information (patterns of defects) as part of the scoping review.

TABLE 1.

Eligibility criteria for the quantitative portion of the scoping review.

Inclusion criteria Exclusion criteria
Population People with dementia due to a cognitive neurodegenerative aetiology (cases)

People with dementia due to causes other than cognitive neurodegeneration, including trauma, intracranial haemorrhage and infection (e.g., Creutzfeldt–Jakob disease)

Animal studies

Comparator People with no evidence of dementia and cognitive neurodegeneration (controls) N/A
Outcome Standard automated or computerised perimetry results, including reliability, pointwise sensitivities, global indices and patterns of visual field defects N/A
Types of study

Case–control

Cohort

Experimental (including randomised clinical trials)

Case report/series

Commentary, letters to the editor, editorials

Conference papers or abstracts

No full text available

Articles published before 1985

Abbreviation: N/A, not applicable.

Search strategy and screening

Four databases (MEDLINE, EMBASE, PsycINFO and CINAHL) were searched from January 1 1985 to July 2024 by the lead reviewer (JP). Search terms were entered as free text or as controlled vocabulary as appropriate to each database. The search terms were as follows: dementia, cognitive neurodegeneration, cognitive dysfunction (or defect), memory defect, attention defect or Alzheimer's disease AND perimetry, frequency doubling technology, visual field or visual fields. Note that other specific phenotypes of Lewy body dementia, vascular dementia and frontotemporal dementia were not specified, as the keyword dementia (as a MeSH term) was expected to capture these conditions; this was manually reviewed post hoc. Furthermore, more broad descriptors of visual field testing, such as ‘eye field’ and ‘field test’ (or other similar permutations) were not used, as it was important to capture specifically formal perimetric and visual field testing, rather than including other variations of field of vision, which would be spurious. However, given the prolific nature of frequency doubling technology within this time period, it was included as a specific search term.

No language restrictions were applied. The search only included papers published from 1985 onwards, as prior to this date, there were few technologies for standardised automated perimetry, and thus would not return the parameters of interest. All identified titles and abstracts were screened by two reviewers (JP and HW) for eligibility. In addition to the review of papers from the databases, the reference lists of the full text articles were also reviewed for completeness.

Data extraction and presentation

Data extraction was performed by two reviewers (JP and HW) independently. Data that were extracted included: last name of the first author, year of publication, country, information on subject recruitment and definition of diagnostic categories, standard automated perimetry technique and standard automated perimetry indices. Quality of the included studies were assessed by two reviewers independently (JP and HW) using the Joanna Briggs Institute critical appraisal checklists for cross sectional, cohort, 38 case series and case report studies. 39 Disagreements were resolved through discussion.

Statistical analysis

Where available, the sample size and distribution (such as mean and standard deviation) parameters were extracted from the studies. Then, the standardised mean difference (SMD) and 95% confidence intervals (CI) were calculated as a measure of effect size. Although standard automated perimetry outcomes were the parameters of interest, there are significant differences across instruments, test grids and thresholding protocols, such that their outputs may not be interchangeable. Therefore, specific distributions of global indices (such as mean deviation or pattern deviation) were not reported for each study. The studies were pooled to obtain the weighted mean effect size, pooled variance and 95% CI. Cochran's Q and heterogeneity (I 2 ) amongst studies were also calculated. All analyses were performed on GraphPad Prism version 8 (graphpad.com) and Microsoft Excel version 2408 (Microsoft.com).

RESULTS

The flowchart for the systematic search and study selection process, as per the Preferred Reporting Items for Systematic Reviews and Meta‐Analysis extension for Scoping Reviews (PRISMA‐ScR) statement, is shown in Figure 1. A total of 2726 records were identified through searching multiple databases. After excluding 276 duplicates, 2450 records were screened by title and abstract, and 67 full text reports were retrieved for further assessment for inclusion or exclusion. Sixty‐three full text articles were excluded for reasons described in Figure 1, leaving four articles included for quantitative synthesis. The perimeter, test protocol and sample sizes for each study are shown in Table 2. Notably, the 30–2 test was performed as often as the 24–2, and there was a mix of frequency doubling technology (FDT, Carl Zeiss Meditec, zeiss.com/meditec‐ag/en/home.html) and white‐on‐white standard automated perimetry performed using the Humphrey Field Analyzer (Carl Zeiss Meditec, zeiss.com/meditec‐ag/en/home.html, with two studies each). Other articles that were excluded from quantitative synthesis are reviewed in separate subsections below for reliability indices and patterns of visual field defects (visual field global indices were not reported due to lack of comparators; see Table 2).

FIGURE 1.

FIGURE 1

Flow chart for the systematic review.

TABLE 2.

Characteristics of studies from the full‐text analysis used for quantitative analysis, as per the criteria in Table 1.

First author surname Year Location Sample size (cases) a Sample size (controls) a Type of neurocognitive disease Visual field instrument/test protocol MMSE testing scores (cases) b MMSE testing scores (controls)
Aykan 34 2013 Turkey 28 (43) 30 (33) AD FDT Matrix 30–2 21.35 (1.39) 28.76 (1.85)
Risacher 35 2012 South Korea 68 29 AD, MCI, CC FDT 2 24–2 24.18 (0.5), 27.82 (0.3), 28.57 (0.4) 28.82 (0.3)
Trick 36 1995 Norway 61 61 AD HFA 30–2 STATPAC Not reported Not reported
Tsironi 37 2012 USA 24 24 PD HFA 24–2 SITA‐Standard 28.3 (2.4) Not reported

Abbreviations: AD, Alzheimer's disease; CC, cognitive complaints; FDT, frequency doubling technology; HFA, Humphrey Field Analyzer; MCI, mild cognitive impairment; MMSE, mini‐mental state examination; PD, Parkinson's disease.

a

The number in brackets indicates the total sample size, with the number outside the brackets indicate the number of results deemed to be reliable as per the authors' criteria.

b

Results shown for the AD, MCI and CC groups for the study by Risacher. 35

Visual field global indices in studies meeting inclusion/exclusion criteria

Four studies 34 , 35 , 36 , 37 reported mean deviation and pattern standard deviation results. The results are shown in Figure 2. The mean deviations were significantly lower in participants with dementia compared to controls (SMD = −1.16, 95% CI: −1.47 to −0.86) and pattern standard deviation (SMD = −0.96, 95% CI: −1.25 to −0.67). The heterogeneity was high for both indices at 92.1% for mean deviation and 92.2% for pattern standard deviation, largely driven by the comparatively large effect size from Risacher et al. 35

FIGURE 2.

FIGURE 2

Standardised mean difference and 95% CI for the studies 34 , 35 , 36 , 37 reporting perimetry global indices mean deviation (a) and pattern standard deviation (b). A negative standardised mean difference indicates a worse result in cases, and a positive standardised mean difference indicates a worse result in controls. The red result indicates the weighted mean effect, pooled across studies.

Visual field reliability indices in studies meeting inclusion/exclusion criteria

Three studies 34 , 35 , 36 reported computed reliability indices, with one separating the reliability results into right and left eyes. 35 Fixation loss rates (SMD −0.30, 95% CI: −0.57 to −0.04), false positive rates (SMD −0.33, 95% CI: −0.60 to −0.06) and false negative rates (SMD −1.12, 95% CI: −1.40 to −0.83) were significantly higher in participants with dementia compared to healthy controls (Figure 3). For the study 35 separating right and left eyes, the false positive rate was higher in the healthy controls compared to participants with dementia. Heterogeneity was high for false positive rate (94.6%) and false negative rate (92.7%), driven primarily by the large effect size by the study by Risacher et al. 35 Heterogeneity was <0% for fixation loss rate.

FIGURE 3.

FIGURE 3

Standardised mean difference and 95% CI for the studies 34 , 35 , 36 , 37 reporting on conventional reliability indices reported in perimetry: Fixation loss rate (a), false positive rate (b) and false negative rate (c). A negative standardised mean difference indicates a worse result in cases, and a positive standardised mean difference indicates a worse result in controls. The red result indicates the weighted mean effect, pooled across studies.

Visual field reliability indices in other articles

Pelak et al. 21 reported 28 Humphrey Field Analyzer perimetry results of nine patients with posterior cortical atrophy progressing to dementia (eight with Alzheimer's disease, one with dementia with Lewy bodies). In the 28 perimetry results, the mean (and SD) of fixation loss, false positive and false negative rates were 15.3% ± 19.6%, 3.2% ± 5.0% and 22.2% ± 19.4%, respectively. Further, 8/28 (29%), 1/28 (4%) and 14/28 (50%) of results were identified as ‘unreliable’ when criteria of >20% fixation loss rate, >15% false positive rate and > 15% false negative rate were used, respectively.

Millington et al. 40 described a case series of 10 patients with posterior cortical atrophy who had undergone visual field testing using the Humphrey Field Analyzer with the 24–2 test grid. All patients has a homonymous visual field defect. The distribution of reliability index results was described with a relatively low false positive rate (mean 2.20% ± 2.26%) and a variable false negative rate (mean 22.95% ± 20.56%).

Patterns of visual field defects

Two studies 35 , 36 reported on the pattern or distribution of visual field defects, though neither reported on the number of pattern deviation defects for each subject. Trick et al. 36 showed the distribution of sensitivity deficit across the 30–2 perimetry test grid when comparing participants with dementia and age‐matched controls. Areas with the greatest reduction in sensitivity were in the inferotemporal periphery, followed by the superotemporal and inferonasal regions. Notably, many of the greyscale examples shown in their study appeared to resemble cloverleaf (or classically ‘inattention’) patterned visual field defects, potentially indicating a loss of attention. Neither the amount of sensitivity deficit nor its statistical significance was quantified.

Risacher et al. 35 described the regions of the 24–2 perimetry test grid which showed statistically significant differences in sensitivity when comparing their diagnostic groups, with the most marked differences observed between the Alzheimer's disease and healthy control groups. The results were divided by right and left eyes. The regions with the lowest p‐value (p < 0.001) were in the superotemporal quadrant in the right eye and within the superior hemifield and inferotemporal region in the left eye.

Aykan et al. 34 did not report directly specific visual field regions affected in neurodegenerative disease, but rather the outcomes of the Glaucoma Hemifield Test, which showed statistically significant asymmetries across the horizontal midline of the test grid. They found that participants with Alzheimer's disease had a higher rate of Glaucoma Hemifield Test results that were outside normal limits compared to the control group for the right and left eyes.

Patterns of visual field defects from additional review of case series and reports

In addition to the formal inclusion and exclusion criteria, select published works were also reviewed reporting patterns of visual field defects in dementia caused by cognitive neurodegenerative disease.

Five case series 20 , 21 , 40 , 41 , 42 reported on the patterns of visual field defects in cognitive neurodegenerative disease. These are summarised in Table 3.

TABLE 3.

Selected case series from the full‐text analysis of studies following title and abstract screening.

First author surname Year Location Number of patients Patient age range (years) Patient gender (M, F) Type of neurocognitive disease Visual field instrument/test protocol
Kaeser 41 2015 Switzerland 10 58 to 82 4, 6 AD (VVAD) ‘Computerised static automated perimetry’
Millington 40 2017 UK 10 53 to 77 4, 6 AD (PCA) HFA 24–2 SITA‐Standard
Olds 20 2020 USA 38 45 to 81 10, 28 AD (PCA) ‘Threshold perimetry’
Pelak 21 2011 USA 9 49 to 76 7, 2 AD (8), DLB (1) HFA 30–2 or 24–2
Tang‐Wai 42 2004 USA 40 40 to 86 12, 28 AD (PCA) Not stated

Abbreviations: AD, Alzheimer's disease; DLB, dementia with Lewy bodies; HFA, Humphrey Field Analyzer; PCA, posterior cortical atrophy; UK, United Kingdom; USA, United States of America; VVAD, visual variant of Alzheimer's disease.

Kaeser et al. 41 reported a case series of 10 patients with cognitive neurodegeneration leading to dementia. The age range of their patients was 58–82 years. Six out of the 10 patients had reliable results on computerised static perimetry, and five of six of the reliable results were incomplete homonymous hemianopia. The remaining four patients underwent confrontation field testing, which should identify partial homonymous defects.

Olds et al. 20 reported data from 38 patients within a clinical registry with the posterior cortical atrophy subtype of Alzheimer's disease. A total of 34 out of the 38 patients had visual field defects, with the most common type (53%) being homonymous hemianopia (83% left‐sided and 17% right‐sided), followed by ‘other’ (unspecified) defects and then generalised constriction (9%) and homonymous hemianopia (9%). Olds et al. 20 reported that only two of the 38 patients returned unreliable visual field test results.

Pelak et al. 21 described the results of nine patients with posterior cortical atrophy progressing to dementia (eight with Alzheimer's disease, one with dementia with Lewy bodies) who had undergone computerised visual field testing. The most common defect pattern in this group was homonymous hemianopia (with left being more common than right), with a diversity of severities. However, most participants showed additional superimposed defects, with isolated peripheral defects in the less affected quadrants.

The case series from Millington et al. 40 of 10 patients with posterior cortical atrophy notably required all patients to have consistent homonymous visual field defects on the 24–2 test grid for inclusion. All patients were described as having asymmetric visual field defects, with eight having greater loss in the left hemifield. Half of the patients had visual field loss in both hemifields, all showing greater defects in the left. The visual field defects were described to be less dense than typically expected in stroke or traumatic loss.

Tang‐Wai et al. 42 reviewed the records of 40 patients diagnosed with posterior cortical atrophy. Nineteen of the 40 presented with visual field defects, of which 14 were described as a hemianopia or quadrantonopia, with the others listed as variable/inconsistent (4) or constricted (1).

Of the eight case reports identified in the full text analysis, seven 43 , 44 , 45 , 46 , 47 , 48 , 49 reported on patients with cognitive neurodegenerative disease (six with Alzheimer's disease, and one having dementia with Lewy bodies) (Table 4). Three studies reported the perimeter used for examination. Homonymous hemianopia was the most common visual field defect reported amongst these studies (three right and three left), with one patient having an incongruous left inferior homonymous quadrantonopia.

TABLE 4.

Selected case reports from the full‐text analysis of studies following title and abstract screening.

First author surname Year Location Patient age (years) Patient gender Type of neurocognitive disease Visual field instrument/test protocol Description of visual field result Mini mental state examination result (MMSE </30)
Bashir 43 1998 USA 66 F DLB HFA 24–2 Left incomplete homonymous hemianopia 26
Kim 44 2019 South Korea 57 F AD (PCA) HFA 30–2 Left incomplete homonymous hemianopia Not stated
Muller 45 2013 Norway 52 F AD (PCA) Not stated Right incomplete homonymous hemianopia 24
Ryan 46 2000 USA 74 F AD Not stated Left homonymous hemianopia 24
Shea 47 2014 China 61 M AD (PCA) Not stated Right homonymous hemianopia 29
Shuren 48 1993 USA 65 F AD Not stated Right homonymous hemianopia 8
Whittaker 49 2002 UK 52 F AD HFA 24–2 Incongruous left inferior homonymous quadrantonopia Not stated

Abbreviations: AD, Alzheimer's disease; DLB, dementia with Lewy bodies; F, female; HFA, Humphrey Field Analyzer; M, male; PCA, posterior cortical atrophy; UK, United Kingdom; USA, United States of America.

Quality assessment of the studies

The most common quality issues in the cross sectional studies 34 , 35 , 36 , 37 were related to the lack of detail in describing the study participants and the validity and reliability outcome measurements (Table S1). Details that would have benefited from further clarification included the time period for recruitment and more demographic information. 34 , 35 , 36 In terms of the outcome measurements, the perimetrist was not identified in two of the studies 35 , 37 and the perimetrist was an investigator for one study. 34 For one investigation, the criteria for reliability of visual field tests were not clearly justified 34 ; moreover, given that reliability may be an outcome of interest in dementia, its exclusion also introduced a potential bias in the final sample.

The case series 20 , 21 , 40 , 41 , 42 were evaluated as having similar limitations to the methods for identifying cases, with all but one failing to identify whether the cases were consecutive (and accordingly whether the cases were a complete cross section) (Table S2). There were also similar issues regarding the reporting of demographic and clinical data. An omission common throughout all of the examined studies was ethnicity/race, which is listed as a demographic characteristic in the Joanna Briggs Institute checklist, despite issues pertaining to its reporting in current scientific literature. For most of the case series, 20 , 21 , 40 , 41 follow up was either not reported or not relevant.

There were similar results when assessing the case studies. 43 , 44 , 45 , 46 , 47 , 48 , 49 There was a lack of detail on the subject's characteristics (all but one) and history (not being presented as a timeline as per the Joanna Briggs Institute checklist). The specific diagnostic tests used (such as the perimeter) were not clearly identified in most studies 43 , 44 , 46 , 49 (Figure S3). In four studies, 44 , 46 , 48 , 49 examination of treatment/intervention and follow‐up data quality was not applicable as the case set out to describe a cross sectional visit.

DISCUSSION

In the present study, we performed a systematic evaluation of the literature regarding standard automated perimetry in dementia. The mean deviation and pattern standard deviation results were significantly worse in people with dementia compared to controls. Fixation loss, false positive and false negative rates were higher in those with dementia compared to controls, indicating worse performance. Homonymous hemianopia was the most common visual field defect pattern reported in the literature, with a preponderance towards the left hemifield being affected more frequently (most likely due to the propensity for patterns of defect to be reported in specific clinical phenotypes of dementia with exquisite patterns). Several knowledge gaps were identified, including the lack of longitudinal studies, pointwise analysis of visual field defects and patterns of low test reliability.

Visual field sensitivity in dementia in standard automated perimetry

Since clinical dementia is an endpoint of neurodegenerative processes in the brain, it follows that areas subserving visual function that are affected would have clinically detectable deficits. 50 These changes have been visualised using neuroimaging techniques, such as magnetic resonance imaging. 51 The relationship between dementia and vision has recently been shown to be bidirectional, whereby one affects the risk of the other. 52 Specific syndromes leading to dementia, such as posterior cortical atrophy, have characteristic pathological changes that involve the visual pathway, such as the primary visual cortex or the optic radiations (leading to hemianopias and quadrantonopias, respectively). 21

Neurocognitive tests 53 , 54 used for the diagnosis of conditions such as Alzheimer's disease incorporate tests of visuospatial skills, including visual memory, attention and constructional vision. Deficits in these skills reflect pathological changes in cortical areas such as the parieto‐occipital junction and the posterior cortex, and have been shown to be helpful in the diagnostic process. 55

Historically, visuospatial deficits were thought to result from cortical degeneration, rather than primary retinal changes. However, these do not necessarily account for the contrast sensitivity loss seen on perimetry. Several of the studies reviewed herein proposed that combined retinal and cortical changes explain the perimetric losses seen in Alzheimer's disease, even independent of the cognitive ability to comprehend and undertake the test (discussed further below). Risacher et al. 35 found sensitivity loss when using frequency doubling technology perimetry, and offered an explanation that the preferential vulnerability of the magnocellular pathway in Alzheimer's disease may explain this finding. Aykan et al. 34 proposed a similar mechanism to explain their results obtained using Matrix perimetry. However, it is now known that frequency doubling technology does not necessarily interrogate the magnocellular pathway. White et al. 56 showed that the non‐linear retinal ganglion cells (in the magnocellular pathway) were not likely to be the physiological substrate governing the frequency doubling illusion in humans. Later work by Swanson et al. 57 showed that a standard Goldmann size III incremental light stimulus was superior to the frequency doubling stimulus at stimulating the magnocellular pathway, compared to the parvocellular pathway. Therefore, the difference between dementia and control participants in Risacher et al. 35 and Aykan et al. 34 could be explained by inherent differences in sensitivity in a contrast detection task—which itself could reflect damage to the higher visual pathways beyond the retina—rather than in the detection of the frequency doubling illusion.

Trick et al. 36 highlighted significant deficits in patients with Alzheimer's disease in comparison to healthy controls. After accounting for reliability concerns, these authors described patterns of visual field defects including diffuse, multifocal and peripheral rim types. They also proposed that these patterns could reflect both organic losses (i.e., structural defects specific to contrast detection) and non‐organic deficits (i.e., defects related to higher cognitive skills such as attention). These are discussed further below. The patterns of visual field defects described and illustrated in their study would expectedly return worse mean deviation and pattern deviation scores.

Although attention in perimetry is discussed in greater detail in the section below on reliability, visual attention or stimulus uncertainty is also known to be an influential factor in the measurement of perimetric sensitivity.

Structural loci of perimetric loss used to infer functional losses

Studies examining the retina and optic nerve in Alzheimer's disease have revealed losses within potentially all layers of the retina. 58 Previously, evidence for the presence of amyloid plaques, a dementia‐related pathological neurodegenerative change, in the eye has been conflicting. 59 More recent work has provided further histological evidence for beta‐amyloid deposits in the retina. 60 , 61 There have also been proposals for developing fluorophore markers for direct visualisation of neurodegenerative lesions using optical retinal imaging. 11

As well as the deposition of amyloid in the retina, other studies have suggested retrograde degeneration from the cortex as a pathway to retinal ganglion cell loss. 62 , 63 , 64 This degenerative process would resemble that of trans‐synaptic retrograde generation from primary brain injury, such as trauma or stroke, which generally results in well‐defined defects due to the exquisite nature of the affected pathways to the retina. 65 Hart et al. 66 provided a comprehensive overview of the diversity of pathological changes in the eye due to Alzheimer's disease.

Irrespective of whether the changes occur in a primary or secondary/retrograde fashion, 67 this has led to proposals that in vivo retinal imaging, such as optical coherence tomography, might reveal structural changes that could explain perimetric loss in the absence of clearly delineated structural changes such as those seen in the posterior cortical atrophy syndrome.

Although the purpose of this review was to describe visual field losses in dementia, the changes detected using clinical imaging may provide insights regarding expected patterns of functional defects. Using the structure–function relationship of the eye, patterns of structural change revealed using optical coherence tomography could help to predict the expected perimetric loss.

A meta‐analysis by Coppola et al. 68 showed a significant reduction in retinal nerve fibre layer thickness in all quadrants in patients with Alzheimer's disease, and across temporal, nasal and inferior quadrants in individuals with mild cognitive impairment, in comparison with healthy controls. Thomson et al. 69 found more variability across studies, with differences in preferentially affected quadrants. The heterogeneity in affected areas contrasts with typical visual field defects seen in other retinal diseases such as glaucoma. Accordingly, patterns of visual field defects may not be typical, even in the context of retinal manifestations of dementia, except where specific visual pathways have been affected. At a global level, it has been suggested that the amount of loss of neuroretinal tissue may be correlated with the stage of cognitive neurodegeneration. 70 , 71

A longitudinal study by Mutlu et al. 72 showed that thinner retinal nerve fibre layer thickness at baseline is associated with an increased risk of dementia in the future, and suggested that such retinal changes may be useful as biomarkers. The results indicated that a 1‐micron decrease in retinal nerve fibre layer was associated with a 3% increased risk of incident dementia, with a 1 SD change showing a much greater risk of approximately 50%. Interestingly, ganglion cell‐inner plexiform layer thickness showed no relationship with risk. However, these may be confounded by other age‐related declines in vision, such as concurrent ocular diseases, which themselves have substantial overlap with cognitive neurodegeneration. At a practical level, dementia is also associated with poorer scan quality, 73 much like reliability outcomes in perimetry. As such, it may also be useful as a proxy for underlying cognitive degeneration when considering the full clinical picture.

More advanced techniques, such as assistance with artificial intelligence, may reveal further insights into patterns of retinal change in the context of cognitive neurodegeneration. 74 Additionally, advances in the structure–function relationship may also provide a framework for using structure to guide functional assessments using visual field testing. 19

Reliability of visual field testing: Quantitative and qualitative patterns

The weighted mean effects showed that all conventional visual field reliability indices were significantly worse in cases with dementia in comparison to healthy controls. In clinical ophthalmic practice, the utility of these indices is questionable for reflecting the true reliability of the test result. 18 , 19 For example, false negative catch trials were designed to identify behaviours such as inattention or malingering. However, it is well‐known that the presence of profound visual field loss can elevate false negative rates. 75 False positive catch trials were designed to reflect trigger‐happy behaviours. However, different thresholding algorithms, such as SITA‐Faster, may also result in elevated false positive rates, even if the undesired behaviour is absent. 23 , 76

While the clinical utility of cut‐offs for specific reliability catch trials is questionable, trends towards higher levels on these indices may also reflect cognitive deficits present in dementia. Part of cognitive neurodegenerative disease processes such as Alzheimer's disease is progressive loss of executive function, which is critical for accurate performance on perimetry. Examples of specific executive function deficiencies important to perimetry include attention, motivation and working memory. Patients need to comprehend and retain the instruments for a task that requires significant concentration, 77 especially with short inter‐stimulus intervals in modern test algorithms. It was therefore not surprising in the meta‐analysis to find poorer results on reliability indices in comparison with cognitively healthy individuals.

The diversity of differences in magnitude of reliability indices between cognitively impaired and healthy individuals may be attributable to the heterogeneity in presentation of dementia, including the stage of disease. Based on the present analyses, it remains challenging to tease out specific cut‐off values representing significant differences across strata of cognitive neurodegeneration, but potentially increasingly worse reliability results and elevated levels across multiple domains may raise the index of clinical suspicion.

Several studies provided examples of visual field defects for qualitative evaluation. Although there is a diversity of potentially pathological visual field defects found in patients with dementia, such as hemianopia and quadrantonopia, some of the patterns of visual field defects, such as cloverleaf defects, could potentially be attributable to poor test‐taking ability, that is, as another surrogate for poor test reliability. 22

Typically, studies tend to exclude and not report test results that fail to meet thresholds of test reliability on quantitative analysis. Pelak et al. 21 provided raw visual field outputs for qualitative examination. Several of their cases had false negative rates above 15%. Although a subset of these cases had profound visual field loss that could explain such a high false negative rate, the pattern of defect was less clear for others, such as their patients 4, 5 and 7. Instead, these cases demonstrated classic peripheral patterns of inattention, called ‘cloverleaf’ defects, potentially reflecting underlying deficits in executive function.

Based on their reported data, the cases of Pelak et al. 21 did not appear to show as many fixation losses, especially when examining the gaze tracker outputs (only available for a few of their cases). Interestingly, some of their cases had very good gaze tracker results, despite relatively prolonged test durations (such as patients 1, 3 and 6). However, others had many more downward ticks on the gaze tracker, which indicate errors in tracking, potentially due to issues with lid position, blinking or frank eye closure (such as in patients 2 and 8).

In combination, there is evidence of worse quantitative reliability indices in people with dementia in comparison with healthy controls. There is also potential evidence for qualitative patterns of visual field defects mirroring the quantitative results, but the interpretation of this evidence is difficult due to limited available data in the literature for analysis.

This represents an opportunity for further study. Instead of automatically excluding results not meeting cut‐offs for reliability indices (which themselves may be arbitrary), future studies could include data from such patients and also include raw data for qualitative analysis. Furthermore, these studies used older test algorithms such as full threshold or SITA‐Standard. Newer test algorithms are faster and use different Bayesian approaches to threshold estimation, which could also affect the final sensitivity output in people with dementia. Specifically, the SITA‐Faster algorithm is known to return higher false positive rates than prior generation SITA algorithms. 23 , 76 , 78 Seeding point errors are also much more common in SITA‐Faster compared to other members of the SITA family, and this has been postulated to be a surrogate for inattention in the initial phases of testing. 24 Specifically, stimulus uncertainty and attention affect contrast sensitivity measurements in perimetry, with directed attention improving sensitivity. 79 , 80 Therefore, the seeding point artefact could also be prevalent in patients with dementia, with contributions due to stimulus uncertainty and impairments in attention.

Relationship between cognitive scores and visual field results

None of the cross sectional studies in the pooled analysis of the present work provided data for examining the relationship between cognitive scores and visual field results. One might predict that worsening dementia would reduce the ability of the individual to complete the task, manifesting with poorer reliability indices and patterns.

Ichitani et al. 30 analysed a large cohort of patients in a glaucoma outpatient clinic and examined associations between the Mini‐Cog score (mini‐cog.com) and various visual field parameters. They found no association between the Mini‐Cog score and mean deviation, pattern standard deviation and false positive rates. However, a lower Mini‐Cog score was associated with higher fixation loss and false positive rates, potentially as expected. This study was conducted in a glaucoma outpatient clinic and has the confounders of eye disease on top of potential cognitive impairment.

Diniz‐Filho et al. 29 examined the relationship between the Montreal Cognitive Assessment (MoCA) score and visual field variability, but included only reliable results. They found that a greater change in MoCA score was associated with greater measurement variability. However, by excluding results with poorer reliability index scores, a complete picture of the relationship between cognitive score and perimetric variability remains lacking.

Raman et al. 31 examined the relationship between cognitive scores and visual field reliability in patients with concurrent glaucoma. Similar to the studies described above, they found that cognitive decline was associated with higher false negative rates after correcting for age and glaucoma severity. There was no relationship with false positive rate and fixation loss in the multivariate model. Interestingly, the relationship with false negatives highlights potential issues in inattention and fatigue in worsening levels of cognitive impairment.

Given the number of potential instruments available for assessing cognitive neurodegeneration in dementia, future studies could focus on examining cognitive functions more directly affecting the conduct of perimetry, such as executive function.

Practical issues with visual field testing in dementia

Although the studies above suggest that reliability is impaired and test variability is increased in the context of cognitive neurodegeneration, there was little evidence of a systematic approach to reducing these issues found here. Recently, a review by Piano et al. 81 identified five themes related to dementia in the context of eye care, of which one was specifically clinical visual testing. The work highlighted recent evidence supporting complementary vision testing in routine clinical practice, including contrast sensitivity, low contrast visual acuity, colour vision and binocular vision for identifying functional visual impairment in people with dementia. Relevant to the present work, the authors acknowledged in broad terms that tests such as automated perimetry may be attempted, but reasons for limited success should be recorded.

A study by Bowen et al. 82 (not included in the present review as it did not meet the methodological criteria) found that 110 out of 116 participants were able to complete a visual field test. Although this seemed to be a high proportion of success, they excluded 251 participants within the cohort who were pre‐emptively deemed by the testing clinician to be unable to undertake testing. The final success rate of 30% for visual field testing was confounded by an assumption of non‐cooperation. However, the authors neither commented further on the visual field data, nor did they perform any further logistic regression analysis against cognitive test scores.

Based on this literature search, there were no studies that suggested methods of adapting visual field testing for people with dementia. Chriqui et al. 83 used adaptations to measurements of visual acuity to obtain clinical data, which leads to the question of whether more objective measurements of visual fields could play a role. Issues of fatigue and learning effects would also be important factors to consider for standard automated perimetry. Multifocal objective perimetry could be useful to address some of these issues in the future. 84 However, one should acknowledge that objective perimetry may report pseudo‐sensitivity values and may not represent the patient's true, inherently subjective, perceptual experience.

Another technique to overcome potential issues of attention and gaze deviation in dementia (which itself is also poorly understood in the context of visual field testing) is microperimetry or fundus tracking perimetry. 85 This has been used in the context of people with visual loss who may have a diminished ability to fixate on the central target. 85 Interestingly, for dementia and cognitive impairment, one study examined its use in patients with type 2 diabetes. Ortiz‐Zuniga et al. 86 correlated gaze tracker parameters against mini‐mental state evaluation (MMSE) scores and found that a longitudinal decrease in cognitive function was also associated with worsening gaze tracker metrics. This is an area that requires further investigation outside of patients with diabetes.

Overall, further studies are required to understand the extent to which people with dementia may or may not be able to undertake visual field testing in clinical practice, what adaptations would be necessary to facilitate testing and the role of objective measures in serving as surrogate measure of visual function.

Limitations and knowledge gaps

There are several limitations to the present work. There is a paucity of longitudinal evidence in the literature for analysis, and we had to rely predominantly on cross sectional data. While simpler to obtain, cross sectional data have several weaknesses, including difficulties in making causal inferences and the inability to investigate the temporal relationship between the outcomes and exposure. There are also risks of biases inherent to cross sectional studies, particularly selection, information and confounding. A specific example of selection bias is the tendency for studies to report only the results of patients returning ‘reliable’ test results, as is the historical practice in the field of perimetry. For example, Aykan et al. 34 stated that one third of their participants could not complete visual field testing reliably, which removes a large portion of data that could provide useful insights into patterns of perimetry results.

Another limitation was that most studies reported on either Alzheimer's disease (or its subtype posterior cortical atrophy) or dementia with Lewy bodies. Other causes of dementia including vascular or frontotemporal dementia have been explored in terms of their ocular manifestations, 87 but have been studied less in the context of perimetry. Specifically, since vascular dementia shares pathophysiological pathways with ocular pathologies, understanding its effect on perimetry would be useful for clinical practice. 88 The diagnosis of frontotemporal dementia has an emphasis on executive function deficits, 17 which could also manifest with similar issues of test reliability as described in the present study. A schematic of common areas affected in various phenotypes of dementia is shown in Figure 4, which highlights the colocalisation of areas important to the visual pathway and perimetry, not only from the perspective of visual perception, but also in executive function and decision‐making for reliably undertaking the task.

FIGURE 4.

FIGURE 4

Schematic lateral and sagittal views of the brain grossly highlighting key areas commonly affected in various phenotypes of dementia.

Specific to the outcome measures, there was heterogeneity amongst the reported perimetry outcomes. A major limitation is that standard automated perimetry results are not reported in a standard manner in the dementia literature. The studies examined in the present review demonstrated profound differences in perimetric technique, such as instrument, test grid, stimulus type and thresholding algorithm. Part of this stemmed from the finding that the included studies spanned many years (1995–2013) during which time many technological advancements in perimetry occurred (such as the SITA family of algorithms). One would expect even greater differences in outputs and reporting given more modern devices. 22 Therefore, results from different perimeters are not directly interchangeable for several reasons. In a meta‐analysis, this can be overcome using standardised mean differences, but the effect of test parameters on perimetric outcomes is not presently understood. For example, a recent algorithm available on the Humphrey Field Analyzer, SITA‐Faster, uses only one reversal at each of the four primary points, and inattention in patients can return a notably high rate of seeding point errors. 24 Given attentional deficits in dementia, this artefact could be disproportionately prevalent. Furthermore, innovations in deploying stimuli of different sizes across the visual field may introduce further stimulus uncertainty, which may accentuate perimetric loss in the context of dementia. 79 , 80 , 89 These relationships require further extensive study, as they may provide more biomarkers for differentiating dementia from other pathology of the visual pathway.

Although the initial intention was to conduct a systematic review and meta‐analysis, there ended up being few eligible studies for inclusion, and instead the topic was approached from a scoping review perspective to generate hypotheses for future avenues of research. As described in the results, it is proposed that future studies could provide further clarity on the proportion of participants with dementia with apparent low test reliability, more insights into qualitative patterns of deficit FF and further examine the relationship between severity of dementia and perimetric results.

Finally, although there were many items noted as having not met the checklist requirement for the Joanna Briggs Institute critical appraisal guidelines, these are not necessarily a criticism of the studies themselves, their quality or a commentary on their contribution to the literature. Instead, these represent a potential opportunity to develop a more consistent manner of reporting these patients and their data. A specific point of interest is the inconsistency in the reporting of visual field data (our primary outcome of interest), which represents opportunities for collaboration between different medical specialties and experts.

Conclusion

There is evidence of reduction in perimetric sensitivity in dementia. There is also evidence of poorer test reliability in patients with dementia from a quantitative perspective, with some evidence of qualitative patterns of unreliability, potentially paralleling underlying cognitive deficits. However, this review highlights the relative paucity of systematic evidence available for analysis and proposes future research directions to understand better the effects of dementia and its specific causes on visual field testing.

AUTHOR CONTRIBUTIONS

Jack Phu: Conceptualization (equal); data curation (equal); formal analysis (equal); investigation (equal); methodology (equal); project administration (equal); resources (equal); software (equal); validation (equal); visualization (equal); writing – original draft (equal); writing – review and editing (equal). Henrietta Wang: Conceptualization (equal); data curation (equal); formal analysis (equal); investigation (equal); methodology (equal); validation (equal); visualization (equal); writing – original draft (equal); writing – review and editing (equal).

FUNDING INFORMATION

This study received no financial support.

CONFLICT OF INTEREST STATEMENT

No conflicting relationship exists for any author.

Supporting information

Appendix S1.

OPO-45-1359-s001.docx (71.5KB, docx)

ACKNOWLEDGEMENTS

Open access publishing facilitated by University of New South Wales, as part of the Wiley ‐ University of New South Wales agreement via the Council of Australian University Librarians.

Phu J, Wang H. Visual field defects in dementia: A scoping review. Ophthalmic Physiol Opt. 2025;45:1359–1375. 10.1111/opo.13550

REFERENCES

  • 1. Livingston G, Huntley J, Liu KY, Costafreda SG, Selbaek G, Alladi S, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing commission. Lancet. 2024;404:572–628. [DOI] [PubMed] [Google Scholar]
  • 2. Collaborators GBDDF . Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. Lancet Public Health. 2022;7:e105–e125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: review. JAMA. 2019;322:1589–1599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association workgroup. Alzheimers Dement. 2024;20:5143–5169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Raji CA, Benzinger TLS. The value of neuroimaging in dementia diagnosis. Continuum. 2022;28:800–821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Dubois B, von Arnim CAF, Burnie N, Bozeat S, Cummings J. Biomarkers in Alzheimer's disease: role in early and differential diagnosis and recognition of atypical variants. Alzheimers Res Ther. 2023;15:175. 10.1186/s13195-023-01314-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Gaire BP, Koronyo Y, Fuchs DT, Shi H, Rentsendorj A, Danziger R, et al. Alzheimer's disease pathophysiology in the retina. Prog Retin Eye Res. 2024;101:101273. 10.1016/j.preteyeres.2024.101273 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Snyder PJ, Alber J, Alt C, Bain LJ, Bouma BE, Bouwman FH, et al. Retinal imaging in Alzheimer's and neurodegenerative diseases. Alzheimers Dement. 2021;17:103–111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Frost S, Kanagasingam Y, Sohrabi H, Vignarajan J, Bourgeat P, Salvado O, et al. Retinal vascular biomarkers for early detection and monitoring of Alzheimer's disease. Transl Psychiatry. 2013;3:e233. 10.1038/tp.2012.150 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Golzan SM, Goozee K, Georgevsky D, Avolio A, Chatterjee P, Shen K, et al. Retinal vascular and structural changes are associated with amyloid burden in the elderly: ophthalmic biomarkers of preclinical Alzheimer's disease. Alzheimers Res Ther. 2017;9:13. 10.1186/s13195-017-0239-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Cao KJ, Kim JH, Kroeger H, Gaffney PM, Lin JH, Sigurdson CJ, et al. ARCAM‐1 facilitates fluorescence detection of amyloid‐containing deposits in the retina. Transl Vis Sci Technol. 2021;10:5. 10.1167/tvst.10.7.5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Chibhabha F, Yang Y, Ying K, Jia F, Zhang Q, Ullah S, et al. Non‐invasive optical imaging of retinal Aβ plaques using curcumin loaded polymeric micelles in APP swe/PS1ΔE9 transgenic mice for the diagnosis of Alzheimer's disease. J Mater Chem B. 2020;8:7438–7452. [DOI] [PubMed] [Google Scholar]
  • 13. Koronyo‐Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, Ko MK, Black KL, et al. Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. NeuroImage. 2011;54:S204–S217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Xu Y, Aung HL, Hesam‐Shariati N, Keay L, Sun X, Phu J, et al. Contrast sensitivity, visual field, color vision, motion perception, and cognitive impairment: a systematic review. J Am Med Dir Assoc. 2024;25:105098. 10.1016/j.jamda.2024.105098 [DOI] [PubMed] [Google Scholar]
  • 15. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology. 2017;89:88–100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Sachdev P, Kalaria R, O'Brien J, Skoog I, Alladi S, Black SE, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28:206–218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–2477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Tan JCK, Yohannan J, Ramulu PY, Kalloniatis M, Crabb DP, Crowston J, et al. Visual field testing in glaucoma using the Swedish interactive Thresholding algorithm (SITA). Surv Ophthalmol. 2025;70:141–152. [DOI] [PubMed] [Google Scholar]
  • 19. Phu J, Khuu SK, Nivison‐Smith L, Kalloniatis M. Standard automated perimetry for glaucoma and diseases of the retina and visual pathways: current and future perspectives. Prog Retin Eye Res. 2025;104:101307. 10.1016/j.preteyeres.2024.101307 [DOI] [PubMed] [Google Scholar]
  • 20. Olds JJ, Hills WL, Warner J, Falardeau J, Alasantro LH, Moster ML, et al. Posterior cortical atrophy: characteristics from a clinical data registry. Front Neurol. 2020;11:358. 10.3389/fneur.2020.00358 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Pelak VS, Smyth SF, Boyer PJ, Filley CM. Computerized visual field defects in posterior cortical atrophy. Neurology. 2011;77:2119–2122. [DOI] [PubMed] [Google Scholar]
  • 22. Phu J, Khuu SK, Yapp M, Assaad N, Hennessy MP, Kalloniatis M. The value of visual field testing in the era of advanced imaging: clinical and psychophysical perspectives. Clin Exp Optom. 2017;100:313–332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Phu J, Kalloniatis M. The frontloading fields study: the impact of false positives and seeding point errors on visual field reliability when using SITA‐faster. Transl Vis Sci Technol. 2022;11:20. 10.1167/tvst.11.2.20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Phu J, Kalloniatis M. A strategy for seeding point error assessment for retesting (SPEAR) in perimetry applied to normal subjects, glaucoma suspects, and patients with glaucoma. Am J Ophthalmol. 2021;221:115–130. [DOI] [PubMed] [Google Scholar]
  • 25. Ehrlich JR, Goldstein J, Swenor BK, Whitson H, Langa KM, Veliz P. Addition of vision impairment to a life‐course model of potentially modifiable dementia risk factors in the US. JAMA Neurol. 2022;79:623–626. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Ferguson EL, Thoma M, Buto PT, Wang J, Glymour MM, Hoffmann TJ, et al. Visual impairment, eye conditions, and diagnoses of neurodegeneration and dementia. JAMA Netw Open. 2024;7:e2424539. 10.1001/jamanetworkopen.2024.24539 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Shang X, Zhu Z, Wang W, Ha J, He M. The association between vision impairment and incidence of dementia and cognitive impairment: a systematic review and meta‐analysis. Ophthalmology. 2021;128:1135–1149. [DOI] [PubMed] [Google Scholar]
  • 28. Vu TA, Fenwick EK, Gan ATL, Man REK, Tan BKJ, Gupta P, et al. The bidirectional relationship between vision and cognition: a systematic review and meta‐analysis. Ophthalmology. 2021;128:981–992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Diniz‐Filho A, Delano‐Wood L, Daga FB, Cronemberger S, Medeiros FA. Association between neurocognitive decline and visual field variability in glaucoma. JAMA Ophthalmol. 2017;135:734–739. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Ichitani A, Takao E, Tanito M. Roles of cognitive function on visual field reliability indices among glaucoma patients. J Clin Med. 2023;12:7119. 10.3390/jcm12227119 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Raman P, Khy Ching Y, Sivagurunathan PD, Ramli N, Mohd Khalid KH. The association between visual field reliability indices and cognitive impairment in glaucoma patients. J Glaucoma. 2019;28:685–690. [DOI] [PubMed] [Google Scholar]
  • 32. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA‐ScR): checklist and explanation. Ann Intern Med. 2018;169:467–473. [DOI] [PubMed] [Google Scholar]
  • 33. Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18:143. 10.1186/s12874-018-0611-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Aykan U, Akdemir MO, Yildirim O, Varlibas F. Screening for patients with mild Alzheimer disease using frequency doubling technology Perimetry. Neuroophthalmology. 2013;37:239–246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Risacher SL, Wudunn D, Pepin SM, MaGee TR, McDonald BC, Flashman LA, et al. Visual contrast sensitivity in Alzheimer's disease, mild cognitive impairment, and older adults with cognitive complaints. Neurobiol Aging. 2013;34:1133–1144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Trick GL, Trick LR, Morris P, Wolf M. Visual field loss in senile dementia of the Alzheimer's type. Neurology. 1995;45:68–74. [DOI] [PubMed] [Google Scholar]
  • 37. Tsironi EE, Dastiridou A, Katsanos A, Dardiotis E, Veliki S, Patramani G, et al. Perimetric and retinal nerve fiber layer findings in patients with Parkinson's disease. BMC Ophthalmol. 2012;12:54. 10.1186/1471-2415-12-54 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evidence Synthesis. 2020;18:2127–2133. [DOI] [PubMed] [Google Scholar]
  • 39. Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z, (Editors). JBI Manual for Evidence Synthesis. JBI; 2020. Available from https://synthesismanual.jbi.global [Google Scholar]
  • 40. Millington RS, James‐Galton M, Maia Da Silva MN, Plant GT, Bridge H. Lateralized occipital degeneration in posterior cortical atrophy predicts visual field deficits. Neuroimage Clin. 2017;14:242–249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Kaeser PF, Ghika J, Borruat FX. Visual signs and symptoms in patients with the visual variant of Alzheimer disease. BMC Ophthalmol. 2015;15:65. 10.1186/s12886-015-0060-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Tang‐Wai DF, Graff‐Radford NR, Boeve BF, Dickson DW, Parisi JE, Crook R, et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology. 2004;63:1168–1174. [DOI] [PubMed] [Google Scholar]
  • 43. Bashir K, Elble RJ, Ghobrial M, Struble RG. Hemianopsia in dementia with Lewy bodies. Arch Neurol. 1998;55:1132–1135. [DOI] [PubMed] [Google Scholar]
  • 44. Kim CY, Jung JH, Lee JH. Homonymous hemianopia as the initial sign of posterior cortical atrophy. Korean J Ophthalmol. 2019;33:481–482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Muller KI, Bekkelund SI. Visual impairment and posterior cortical atrophy preceding rapid progressive dementia. BMJ Case Rep. 2013;2013:bcr2012007624. 10.1136/bcr-2012-007624 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Ryan JM, Duffy CJ, Tariot PN. Hemi‐inattention presenting as homonymous hemianopia in early dementia. J Neuropsychiatry Clin Neurosci. 2000;12:413–414. [DOI] [PubMed] [Google Scholar]
  • 47. Shea YF, Chu L‐W. Visual field defect as an uncommon presentation of posterior cortical atrophy. Geriatr Gerontol Int. 2014;14:1003–1004. [DOI] [PubMed] [Google Scholar]
  • 48. Shuren J, Heilman KM. Visual field loss in Alzheimer's disease. J Am Geriatr Soc. 1993;41:1114–1115. [DOI] [PubMed] [Google Scholar]
  • 49. Whittaker KW, Burdon MA, Shah P. Visual field loss and Alzheimer's disease. Eye (Lond). 2002;16:206–208. [DOI] [PubMed] [Google Scholar]
  • 50. Kusne Y, Wolf AB, Townley K, Conway M, Peyman GA. Visual system manifestations of Alzheimer's disease. Acta Ophthalmol. 2017;95:e668–e676. [DOI] [PubMed] [Google Scholar]
  • 51. Mito R, Raffelt D, Dhollander T, Vaughan DN, Tournier JD, Salvado O, et al. Fibre‐specific white matter reductions in Alzheimer's disease and mild cognitive impairment. Brain. 2018;141:888–902. [DOI] [PubMed] [Google Scholar]
  • 52. Chen SP, Azad AD, Pershing S. Bidirectional association between visual impairment and dementia among older adults in the United States over time. Ophthalmology. 2021;128:1276–1283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53. Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke's cognitive examination revised (ACE‐R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry. 2006;21:1078–1085. [DOI] [PubMed] [Google Scholar]
  • 54. Tombaugh TN, McIntyre NJ. The mini‐mental state examination: a comprehensive review. J Am Geriatr Soc. 1992;40:922–935. [DOI] [PubMed] [Google Scholar]
  • 55. Salimi S, Irish M, Foxe D, Hodges JR, Piguet O, Burrell JR. Can visuospatial measures improve the diagnosis of Alzheimer's disease? Alzheimers Dement (Amst). 2018;10:66–74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56. White AJ, Sun H, Swanson WH, Lee BB. An examination of physiological mechanisms underlying the frequency‐doubling illusion. Invest Ophthalmol Vis Sci. 2002;43:3590–3599. [PubMed] [Google Scholar]
  • 57. Swanson WH, Sun H, Lee BB, Cao D. Responses of primate retinal ganglion cells to perimetric stimuli. Invest Ophthalmol Vis Sci. 2011;52:764–771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58. Asanad S, Ross‐Cisneros FN, Nassisi M, Barron E, Karanjia R, Sadun AA. The retina in Alzheimer's disease: Histomorphometric analysis of an ophthalmologic biomarker. Invest Ophthalmol Vis Sci. 2019;60:1491–1500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. Jiang J, Wang H, Li W, Cao X, Li C. Amyloid plaques in retina for diagnosis in Alzheimer's patients: a meta‐analysis. Front Aging Neurosci. 2016;8:267. 10.3389/fnagi.2016.00267 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Schultz N, Byman E, Netherlands Brain B, Wennstrom M. Levels of retinal amyloid‐beta correlate with levels of retinal IAPP and hippocampal amyloid‐beta in neuropathologically evaluated individuals. J Alzheimers Dis. 2020;73:1201–1209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61. den Haan J, Morrema THJ, Verbraak FD, de Boer JF, Scheltens P, Rozemuller AJ, et al. Amyloid‐beta and phosphorylated tau in post‐mortem Alzheimer's disease retinas. Acta Neuropathol Commun. 2018;6:147. 10.1186/s40478-018-0650-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62. Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic‐nerve degeneration in Alzheimer's disease. N Engl J Med. 1986;315:485–487. [DOI] [PubMed] [Google Scholar]
  • 63. Blanks JC, Hinton DR, Sadun AA, Miller CA. Retinal ganglion cell degeneration in Alzheimer's disease. Brain Res. 1989;501:364–372. [DOI] [PubMed] [Google Scholar]
  • 64. Katz B, Rimmer S, Iragui V, Katzman R. Abnormal pattern electroretinogram in Alzheimer's disease: evidence for retinal ganglion cell degeneration? Ann Neurol. 1989;26:221–225. [DOI] [PubMed] [Google Scholar]
  • 65. Zangerl B, Whatham A, Kim J, Choi A, Assaad NN, Hennessy MP, et al. Reconciling visual field defects and retinal nerve fibre layer asymmetric patterns in retrograde degeneration: an extended case series. Clin Exp Optom. 2017;100:214–226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66. Hart NJ, Koronyo Y, Black KL, Koronyo‐Hamaoui M. Ocular indicators of Alzheimer's: exploring disease in the retina. Acta Neuropathol. 2016;132:767–787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67. Romaus‐Sanjurjo D, Regueiro U, Lopez‐Lopez M, Vazquez‐Vazquez L, Ouro A, Lema I, et al. Alzheimer's disease seen through the eye: ocular alterations and neurodegeneration. Int J Mol Sci. 2022;23:2486. 10.3390/ijms23052486 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68. Coppola G, Di Renzo A, Ziccardi L, Martelli F, Fadda A, Manni G, et al. Optical coherence tomography in Alzheimer's disease: a meta‐analysis. PLoS One. 2015;10:e0134750. 10.1371/journal.pone.0134750 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69. Thomson KL, Yeo JM, Waddell B, Cameron JR, Pal S. A systematic review and meta‐analysis of retinal nerve fiber layer change in dementia, using optical coherence tomography. Alzheimers Dement (Amst). 2015;1:136–143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70. Santangelo R, Huang SC, Bernasconi MP, Falautano M, Comi G, Magnani G, et al. Neuro‐retina might reflect Alzheimer's disease stage. J Alzheimers Dis. 2020;77:1455–1468. [DOI] [PubMed] [Google Scholar]
  • 71. Kim JI, Kang BH. Decreased retinal thickness in patients with Alzheimer's disease is correlated with disease severity. PLoS One. 2019;14:e0224180. 10.1371/journal.pone.0224180 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72. Mutlu U, Colijn JM, Ikram MA, Bonnemaijer PWM, Licher S, Wolters FJ, et al. Association of retinal neurodegeneration on optical coherence tomography with dementia: a population‐based study. JAMA Neurol. 2018;75:1256–1263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73. Kiat Foo RJ, Wong D, Binte Abdul Gani NF, Tan B, Ismail MB, Garhofer G, et al. Association between dementia and optical coherence tomography scan quality. Aging Dis. 2025;17:1–12. 10.14336/AD.2024.1744 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74. Hasan MM, Phu J, Sowmya A, Meijering E, Kalloniatis M. Artificial intelligence in the diagnosis of glaucoma and neurodegenerative diseases. Clin Exp Optom. 2024;107:130–146. [DOI] [PubMed] [Google Scholar]
  • 75. Bengtsson B, Heijl A. False‐negative responses in glaucoma perimetry: indicators of patient performance or test reliability? Invest Ophthalmol Vis Sci. 2000;41:2201–2204. [PubMed] [Google Scholar]
  • 76. Heijl A, Patella VM, Flanagan JG, Iwase A, Leung CK, Tuulonen A, et al. False positive responses in standard automated perimetry. Am J Ophthalmol. 2022;233:180–188. [DOI] [PubMed] [Google Scholar]
  • 77. Kutzko KE, Brito CF, Wall M. Effect of instructions on conventional automated perimetry. Invest Ophthalmol Vis Sci. 2000;41:2006–2013. [PubMed] [Google Scholar]
  • 78. Phu J, Khuu SK, Agar A, Kalloniatis M. Clinical evaluation of Swedish Interactive Thresholding Algorithm‐faster compared with Swedish Interactive Thresholding Algorithm‐standard in normal subjects, glaucoma suspects, and patients with glaucoma. Am J Ophthalmol. 2019;208:251–264. [DOI] [PubMed] [Google Scholar]
  • 79. Phu J, Kalloniatis M, Khuu SK. Reducing spatial uncertainty through attentional cueing improves contrast sensitivity in regions of the visual field with glaucomatous defects. Transl Vis Sci Technol. 2018;7:8. 10.1167/tvst.7.2.8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80. Phu J, Kalloniatis M, Khuu SK. The effect of attentional cueing and spatial uncertainty in visual field testing. PLoS One. 2016;11:e0150922. 10.1371/journal.pone.0150922 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81. Piano MEF, Nguyen BN, Gocuk SA, Joubert L, McKendrick AM. Primary eyecare provision for people living with dementia: what do we need to know? Clin Exp Optom. 2023;106:711–725. [DOI] [PubMed] [Google Scholar]
  • 82. Bowen M, Edgar DF, Hancock B, Haque S, Shah R, Buchanan S, et al. The prevalence of visual impairment in people with dementia (the PrOVIDe study): a cross‐sectional study of people aged 60–89 years with dementia and qualitative exploration of individual, carer and professional perspectives. Southampton (UK): NIHR Journals Library; 2016. [PubMed] [Google Scholar]
  • 83. Chriqui E, Law C, Kergoat MJ, Leclerc BS, Kergoat H. Visual impairment in older institutionalised Canadian seniors with dementia. Ophthalmic Physiol Opt. 2017;37:225–233. [DOI] [PubMed] [Google Scholar]
  • 84. Maddess T, Rohan EMF, Kulh MA, van Kleef J, Rai BB, Carle C. Diagnostic power of rapid multifocal objective perimetry in Alzheimer's. Invest Ophthalmol Vis Sci. 2024;65:83. [Google Scholar]
  • 85. Pfau M, Jolly JK, Wu Z, Denniss J, Lad EM, Guymer RH, et al. Fundus‐controlled perimetry (microperimetry): application as outcome measure in clinical trials. Prog Retin Eye Res. 2021;82:100907. 10.1016/j.preteyeres.2020.100907 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86. Ortiz‐Zuniga AM, Simo‐Servat O, Rojano‐Toimil A, Vazquez‐de Sebastian J, Castellano‐Tejedor C, Hernandez C, et al. The gaze fixation assessed by microperimetry: a useful tool for the monitoring of the cognitive function in patients with type 2 diabetes. J Pers Med. 2021;11:698. 10.3390/jpm11080698 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87. Chalkias E, Topouzis F, Tegos T, Tsolaki M. The contribution of ocular biomarkers in the differential diagnosis of Alzheimer's disease versus other types of dementia and future prospects. J Alzheimers Dis. 2021;80:493–504. [DOI] [PubMed] [Google Scholar]
  • 88. Czako C, Kovacs T, Ungvari Z, Csiszar A, Yabluchanskiy A, Conley S, et al. Retinal biomarkers for Alzheimer's disease and vascular cognitive impairment and dementia (VCID): implication for early diagnosis and prognosis. Geroscience. 2020;42:1499–1525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89. Wall M, Woodward KR, Brito CF. The effect of attention on conventional automated perimetry and luminance size threshold perimetry. Invest Ophthalmol Vis Sci. 2004;45:342–350. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Appendix S1.

OPO-45-1359-s001.docx (71.5KB, docx)

Articles from Ophthalmic & Physiological Optics are provided here courtesy of Wiley

RESOURCES